Based on results from the activation of the STING signaling pathway and the efficiency of compound synthesis, CF501, CF502, CF508, and CF510 were selected to investigate whether these STING agonists could stimulate the immune system to enhance the protective immune response to a candidate COVID-19 vaccine. The gene discussed is STING1; the disease is COVID-19.